Mallinckrodt PLC (MNK)

66.49
NYSE : Health Care
Prev Close 67.53
Day Low/High 65.85 / 68.00
52 Wk Low/High 50.90 / 125.95
Avg Volume 1.85M
Exchange NYSE
Shares Outstanding 109.33M
Market Cap 7.38B
EPS 2.80
P/E Ratio 20.46
Div & Yield N.A. (N.A)

Latest News

Health Care Resource Use And Costs Of H.P. Acthar® Gel (Repository Corticotropin Injection) For Multiple Sclerosis Relapse

Health Care Resource Use And Costs Of H.P. Acthar® Gel (Repository Corticotropin Injection) For Multiple Sclerosis Relapse

- Retrospective Health Economic Data Published in Advances in Therapy Show Acthar May Be an Important Treatment Option for Patients with Multiple Sclerosis Relapses -

Trending Tickers: UAL, MNK, ENDP, BWA

Optimism that the United Kingdom will remain part of the EU was tempered by falling oil prices.

Mallinckrodt Needs More Medicine

A rally above $65 with strong volume is needed to change the direction of MNK.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: MNK, MTH, TLF, WMB Downgrades: BLMN, TRVN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Mallinckrodt Submits Investigational New Drug Application For Synacthen® Depot

Mallinckrodt Submits Investigational New Drug Application For Synacthen® Depot

- Company will pursue an indication for the drug in treatment of Duchenne Muscular Dystrophy -

Mallinckrodt Presents New Data From 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar® Gel Trial In Lupus

Mallinckrodt Presents New Data From 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar® Gel Trial In Lupus

-- Patients continuing to receive Acthar in the open label phase maintained the improvements seen in the blinded phase -

5 Health Care Stocks Whose Charts Tell You to Wait to Buy

5 Health Care Stocks Whose Charts Tell You to Wait to Buy

Are John Paulson's health care positions all buys? The charts, according to TheStreet's Bruce Kamich, say you may want to wait.

5 Health Care Stocks John Paulson Is Betting On in 2016

5 Health Care Stocks John Paulson Is Betting On in 2016

When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.

Mallinckrodt Donates 250,000 Drug Deactivation Systems To ACT Missouri To Support Fight Against Prescription Drug Abuse

Mallinckrodt Donates 250,000 Drug Deactivation Systems To ACT Missouri To Support Fight Against Prescription Drug Abuse

- Company's Statewide Collaboration Enables Safe Disposal of Unused Medication for Missouri Families -

Mallinckrodt Plc To Change Fiscal Year

Mallinckrodt Plc To Change Fiscal Year

- Company's Fiscal Year End Moves to December -

Trader's Notebook: Mixing Coffee With Oil

Stalking Mallinckrodt for a short and Alcoa for a buy as well. 

Andrew Left Challenges Mallinckrodt to Do Proper Study of Its Main Drug

Andrew Left Challenges Mallinckrodt to Do Proper Study of Its Main Drug

Left might have changed his mind on Valeant but he's still distrustful of Mallinckrodt and issued a $1 million challenge on the company's premier drug, Acthar.

Mallinckrodt Is Robbing From the Health Care System, Says Andrew Left

One day after announcing a long position on Valeant, Andrew Left of Citron Research makes it clear he's still not a fan of Mallinckrodt.

First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar® Gel For Rare Cause Of Nephrotic Syndrome

First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar® Gel For Rare Cause Of Nephrotic Syndrome

-- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis --

Mallinckrodt (MNK) Showing Unusual Social Activity Today

Mallinckrodt (MNK) Showing Unusual Social Activity Today

Trade-Ideas LLC identified Mallinckrodt (MNK) as an unusual social activity candidate

'Mad Money' Lightning Round: Buy Palo Alto Networks for the Long Term

'Mad Money' Lightning Round: Buy Palo Alto Networks for the Long Term

Cramer likes Zoe's Kitchen and Celgene and prefers Occidental Petroleum to Devon Energy.

Jim Cramer's 'Mad Money' Recap: These Dow Stocks Doing Better Than You Believe

Jim Cramer's 'Mad Money' Recap: These Dow Stocks Doing Better Than You Believe

We've seen a volatile market where perception is worse than reality. That's why Cramer is looking at 30 Dow stocks to show you things aren't that bad.

Trader's Notebook: Three Names to Watch for Short Sellers

Short ideas on Abercrombie & Fitch, Apple and Mallinckrodt, plus an update on oil.

Today's Dead Cat Bounce Stock Is Mallinckrodt (MNK)

Today's Dead Cat Bounce Stock Is Mallinckrodt (MNK)

Trade-Ideas LLC identified Mallinckrodt (MNK) as a "dead cat bounce" (down big yesterday but up big today) candidate

AAPL, AMZN, SQ: Jim Cramer's Views

AAPL, AMZN, SQ: Jim Cramer's Views

Jim Cramer shares his views on how collateral damage is harming stocks and discusses what the jobs report means. Apple, Amazon and Square are among the stocks discussed here.

Cramer: Collateral Damage Is Giving These Stocks a Bad Name

But for the brave, they could offer a solid bottom-fishing opportunity.

Mallinckrodt (MNK) Weak On High Volume Today

Mallinckrodt (MNK) Weak On High Volume Today

Trade-Ideas LLC identified Mallinckrodt (MNK) as a weak on high relative volume candidate

Mallinckrodt (MNK) Marked As Today's Post-Market Laggard

Mallinckrodt (MNK) Marked As Today's Post-Market Laggard

Trade-Ideas LLC identified Mallinckrodt (MNK) as a post-market laggard candidate

3 Stocks Pulling The Drugs Industry Downward

3 Stocks Pulling The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Trade-Ideas: Mallinckrodt (MNK) Is Today's

Trade-Ideas: Mallinckrodt (MNK) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Mallinckrodt (MNK) as a "perilous reversal" (up big yesterday but down big today) candidate

Here's Why Mallinckrodt (MNK) Stock Is Surging Today

Here's Why Mallinckrodt (MNK) Stock Is Surging Today

Mallinckrodt (MNK) stock is higher in mid-morning trading on Tuesday after the company released its 2016 second quarter earnings before the market open today.